NUUVERA ACQUIRES GMP LABORATORY IN MALTA
Sets stage for servicing EU medical cannabis market
Toronto, Canada (February 27, 2018) – Nuuvera Inc. (“Nuuvera”) (TSXV:NUU) announced today that it has acquired ASG Pharma, a high-capacity Maltese GMP laboratory. ASG Pharma, one of the few GMP labs in Malta, is expected to be one of Nuuvera’s hubs for the production and distribution of oil-based medical cannabis products to the emerging European medical cannabis market.
Nuuvera’s CEO, Lorne Abony, said “It is clear that Malta specifically and the European Union generally intend to make consumer protection a priority, and this approach aligns perfectly with our vision to create a centre of excellence in Malta for the production and distribution of pharmaceutical grade cannabis products. To that end, ASG Pharma will adhere to the highest international standards for processing and extraction, distribution and security protocols.”
Through its subsidiary, ARA Avanti RX Analytics, Nuuvera is the only international medical cannabis company that has a standalone Health Canada GMP approved facility that is authorized to conduct commercial scale activities with respect to cannabis and other cannabinoids. Through its acquisition of ASG Pharma, Nuuvera will bring this expertise to Malta.
Antonio Costanzo, Nuuvera’s Head of International Development, said “The ASG Pharma acquisition is one in a series of deals which will continue to increase Nuuvera’s global footprint in the medical cannabis industry. We will continue to build on our strong Canadian base with strategic international operations and partners in order to provide the consumer with the highest quality medical cannabis at a competitive price.”
– 30 –
For media inquiries contact
For investor inquiries contact:
Nuuvera is a global cannabis company founded on Canadian principles, and built with the whole world in mind. Nuuvera is currently working with partners in Germany, Israel and Italy, and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets. Through its subsidiaries, ARA – Avanti Rx Analytics Inc. and Avalon Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the Narcotic Control Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health Canada review process to become a Licensed Producer of medical marijuana under the ACMPR, and has recently received its “letter to build” approval.
For more information on Nuuvera, please visit: www.nuuvera.com